Teleflex Incorporated has undergone significant dynamics as a participant in the bio-tech market. The
Bank of New York Mellon Corp offloaded 24,894 of its TFX shares. Despite a share price decline, Teleflex continues to carry out an evaluation of its valuation prospects. Recently, it confirmed its participation in the Jefferies Global Healthcare Conference in London. Unfortunately, its Q3 earnings reveal a disappointing view for 2025 alongside a significant revenue beat. A major highlight is Teleflex’s secured contract with Vizient to supply
Vascular Access Products. However, it suffered a 10.6% decline after a goodwill impairment worth $403.9 Million and a slashed outlook. It also split into two independent companies in 2026 and made an announcement of a $0.34 dividend. Boston Partners, Illinois Municipal Retirement Fund, Next Capital Management LLC, AlphaQuest LLC, and others raised their TFX stock holdings. They declared another $0.34 quarterly dividend after their Q3 earnings and revenues exceeded estimates. In terms of price, Teleflex's target was lowered to $120.00 at Truist Financial. The company has also initiated a fraud investigation and plans to reset its organization by 2025. Lastly, Teleflex's Barrigel product line was released in Japan, and they completed the acquisition of BIOTRONIK’s Vascular Intervention Business.
Teleflex Incorporated TFX News Analytics from Fri, 21 Feb 2025 08:00:00 GMT to Sat, 15 Nov 2025 13:52:59 GMT -
Rating 4
- Innovation 7
- Information 6
- Rumor -3
